scPharmaceuticals Inc.

NasdaqGS:SCPH Rapporto sulle azioni

Cap. di mercato: US$268.7m

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

scPharmaceuticals Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

John Tucker

Amministratore delegato

US$1.8m

Compenso totale

Percentuale dello stipendio del CEO32.8%
Mandato del CEO7.6yrs
Proprietà del CEO0.2%
Durata media del managementNessun dato
Durata media del Consiglio di amministrazione6.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?

Jun 27
Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?

scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable

Jun 27
scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable

The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 16
The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts

Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?

Nov 25
Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?

scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients

Oct 20

FDA approves scPharmaceuticals Furoscix to treat congestion in heart failure

Oct 10

Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?

Jan 11
Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?

Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?

Sep 02
Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?

scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX

Aug 26

Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like

Mar 09
Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like

How Many scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Do Institutions Own?

Nov 24
How Many scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Do Institutions Own?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di John Tucker rispetto agli utili di scPharmaceuticals?
DataCompenso totaleStipendioGuadagni aziendali
Jun 30 2024n/an/a

-US$61m

Mar 31 2024n/an/a

-US$58m

Dec 31 2023US$2mUS$604k

-US$55m

Sep 30 2023n/an/a

-US$50m

Jun 30 2023n/an/a

-US$45m

Mar 31 2023n/an/a

-US$40m

Dec 31 2022US$2mUS$580k

-US$37m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$31m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$2mUS$550k

-US$28m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$31m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$2mUS$531k

-US$32m

Sep 30 2020n/an/a

-US$35m

Jun 30 2020n/an/a

-US$32m

Mar 31 2020n/an/a

-US$31m

Dec 31 2019US$1mUS$514k

-US$33m

Sep 30 2019n/an/a

-US$27m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$29m

Dec 31 2018US$1mUS$494k

-US$29m

Sep 30 2018n/an/a

-US$31m

Jun 30 2018n/an/a

-US$31m

Mar 31 2018n/an/a

-US$28m

Dec 31 2017US$2mUS$380k

-US$24m

Compensazione vs Mercato: La retribuzione totale di John ($USD 1.84M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 1.54M ).

Compensazione vs guadagni: La retribuzione di John è aumentata nonostante l'azienda non sia redditizia.


AMMINISTRATORE DELEGATO

John Tucker (61 yo)

7.6yrs

Mandato

US$1,838,662

Compensazione

Mr. John H. Tucker has been the Chief Executive Officer and President of scPharmaceuticals Inc. (alternate name: scPharmaceuticals LLC) since January 30, 2017 and serves as its Principal Executive Officer...


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
John Tucker
President8.6yrsUS$1.84m0.18%
$ 486.8k
Leonard Schaeffer
Independent Director9.7yrsUS$184.55k0.11%
$ 308.5k
Jack Khattar
Independent Chairman of the Board8.2yrsUS$227.05k0.010%
$ 26.8k
Mette Agger
Independent Director10.4yrsUS$189.55k0%
$ 0
Klaus Veitinger
Independent Director6.8yrsUS$187.05k0%
$ 0
Marvin Konstam
Member of Scientific Advisory Boardno dataNessun datoNessun dato
William Abraham
Independent Director3.5yrsUS$182.05k0%
$ 0
Minnie Baylor-Henry
Independent Director6.1yrsUS$187.05k0%
$ 0
Frederick Hudson
Independent Director6.2yrsUS$197.05k0%
$ 0
Sara Bonstein
Independent Director4.1yrsUS$187.05k0%
$ 0
G. Felker
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Dan Bensimhon
Member of Scientific Advisory Boardno dataNessun datoNessun dato

6.8yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SCPH sono considerati esperti (durata media dell'incarico 6.8 anni).